Sage Therapeutics (NASDAQ:SAGE) Issues Earnings Results

Sage Therapeutics (NASDAQ:SAGE) announced its quarterly earnings results on Tuesday. The biopharmaceutical company reported ($1.56) earnings per share for the quarter, missing the consensus estimate of ($1.54) by ($0.02), Zacks reports. Sage Therapeutics had a negative net margin of 317.29% and a negative return on equity of 50.29%.

Sage Therapeutics Trading Down 0.4 %

NASDAQ SAGE opened at $7.16 on Thursday. The firm has a market cap of $437.98 million, a PE ratio of -1.28 and a beta of 0.94. Sage Therapeutics has a 1-year low of $4.62 and a 1-year high of $27.39. The stock has a 50-day moving average of $6.34 and a 200-day moving average of $6.93.

Analyst Ratings Changes

SAGE has been the subject of several recent analyst reports. HC Wainwright reaffirmed a “neutral” rating and set a $12.00 price objective (down previously from $14.00) on shares of Sage Therapeutics in a research note on Wednesday. Wedbush reaffirmed a “neutral” rating and issued a $6.00 price target on shares of Sage Therapeutics in a report on Wednesday. StockNews.com lowered Sage Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, October 31st. Needham & Company LLC restated a “hold” rating on shares of Sage Therapeutics in a research note on Wednesday. Finally, Royal Bank of Canada upgraded Sage Therapeutics from an “underperform” rating to a “sector perform” rating and set a $4.00 price target for the company in a research report on Thursday, November 21st. Three investment analysts have rated the stock with a sell rating, sixteen have given a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat.com, Sage Therapeutics presently has a consensus rating of “Hold” and an average target price of $9.65.

Sage Therapeutics Company Profile

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.